A family of mutations seen in about 20% of human cancers drives malignancy by changing the accessibility of genes to a particular regulatory protein, according to a study by Weill Cornell Medicine investigators.
Back to News
Weill Cornell MedicineOffice of External Affairs Phone: (646) 962-9476